Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 18;40(28):3246–3256. doi: 10.1200/JCO.22.00338

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2. — Subgroup analysis of PFS in all patients. PFS, as assessed by blinded independent central review, in clinically relevant subgroups of patients with ER-positive/HER2-negative advanced breast cancer. Interaction P values were all nonsignificant indicating that elacestrant benefit on PFS is independent of subgroup. ^aNonstratified analysis. ^bIn the advanced setting. ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PFS, progression-free survival; SOC, standard of care.